(RTTNews) - Hepion Pharmaceuticals, Inc. (HEPA), a clinical stage biopharmaceutical company, Wednesday said it has entered into a binding letter of intent (LOI) with New Day Diagnostics LLC, a ...
Paper-based diagnostic tests such as rapid COVID-19 assays have broadened access to diagnostic tests beyond the lab. But historically, they have been limited to a binary readout: either yes or no. At ...
If you've ever taken an at-home diagnostic test for COVID-19, you can partially credit the technology to the Johns Hopkins University Center for Innovative Diagnostics for Infectious Diseases (CIDID).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback